173 related articles for article (PubMed ID: 25076440)
1. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
Ferreira e Vasconcellos Ede C; Pimentel MI; Valete-Rosalino CM; Madeira Mde F; Schubach Ade O
Rev Inst Med Trop Sao Paulo; 2014; 56(4):361-2. PubMed ID: 25076440
[TBL] [Abstract][Full Text] [Related]
2. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
Duque MC; Vasconcellos ÉC; Pimentel MI; Lyra MR; Pacheco SJ; Marzochi MC; Rosalino CM; Schubach AO
Rev Soc Bras Med Trop; 2016; 49(6):774-776. PubMed ID: 28001228
[TBL] [Abstract][Full Text] [Related]
3. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
López L; Robayo M; Vargas M; Vélez ID
Trials; 2012 May; 13():58. PubMed ID: 22594858
[TBL] [Abstract][Full Text] [Related]
4. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).
Vasconcellos Ede C; Pimentel MI; Schubach Ade O; de Oliveira Rde V; Azeredo-Coutinho RB; Silva Fda C; Salgueiro Mde M; Moreira JS; Madeira Mde F; Baptista C; Valete-Rosalino CM
Am J Trop Med Hyg; 2012 Aug; 87(2):257-60. PubMed ID: 22855754
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
Munir A; Janjua SA; Hussain I
Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100
[TBL] [Abstract][Full Text] [Related]
6. Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial.
Ramalho DB; Silva RED; Senna MCR; Moreira HSA; Pedras MJ; Avelar DM; Saraiva L; Rabello A; Cota G
Mem Inst Oswaldo Cruz; 2018 Jun; 113(9):e180200. PubMed ID: 29947651
[TBL] [Abstract][Full Text] [Related]
7. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
Aste N; Pau M; Ferreli C; Biggio P
Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
[No Abstract] [Full Text] [Related]
8. [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
Ezzine Sebai N; Mrabet N; Khaled A; Zeglaoui F; Kharfi M; Fazaa B; Kamoun MR
Tunis Med; 2010 Jan; 88(1):9-11. PubMed ID: 20415206
[TBL] [Abstract][Full Text] [Related]
9. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre.
Silva RE; Toledo A; Senna MC; Rabello A; Cota G
Mem Inst Oswaldo Cruz; 2016 Aug; 111(8):512-6. PubMed ID: 27508321
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
Solomon M; Ollech A; Pavlotsky F; Barzilai A; Schwartz E; Baum S; Astman N
Acta Derm Venereol; 2024 Apr; 104():adv35089. PubMed ID: 38682801
[TBL] [Abstract][Full Text] [Related]
11. An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
Oliveira-Ribeiro C; Pimentel MIF; Oliveira LFA; Vasconcellos ÉCFE; Conceição-Silva F; Schubach AO; Fagundes A; de Mello CX; Mouta-Confort E; Miranda LFC; Valete-Rosalino CM; Martins ACDC; Oliveira RVC; Quintella LP; Lyra MR
PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009734. PubMed ID: 34555016
[TBL] [Abstract][Full Text] [Related]
12. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
Mujtaba G; Khalid M
Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
[No Abstract] [Full Text] [Related]
13. Comparison of lesion improvement in lupoid leishmaniasis patients with two treatment approaches: trichloroacetic Acid and intralesional meglumine antimoniate.
Banihashemi M; Yazdanpanah MJ; Amirsolymani H; Yousefzadeh H
J Cutan Med Surg; 2015; 19(1):35-9. PubMed ID: 25775661
[TBL] [Abstract][Full Text] [Related]
14. [Symptomatic hypokalemia caused by meglumine antimoniate].
Bouvresse S; Matichard E; Mahé E; Marinho E; Soria A; Devillière M; Descamps V; Crickx B
Ann Dermatol Venereol; 2007 Apr; 134(4 Pt 1):387-8. PubMed ID: 17483764
[No Abstract] [Full Text] [Related]
15. Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013).
Brahim LR; Valete-Rosalino CM; Antônio LF; Pimentel MIF; Lyra MR; Paes LEC; Costa ADD; Vieira IF; Dias CMG; Duque MCO; Marzochi MCA; Schubach AO
Mem Inst Oswaldo Cruz; 2017 Dec; 112(12):838-843. PubMed ID: 29211245
[TBL] [Abstract][Full Text] [Related]
16. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
[TBL] [Abstract][Full Text] [Related]
17. Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
Pimentel MIF; Vasconcellos ÉCFE; Ribeiro CO; Lyra MR; Saheki MN; Salgueiro MM; Antonio LF; Schubach AO
Rev Soc Bras Med Trop; 2017; 50(2):269-272. PubMed ID: 28562769
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
Faghihi G; Tavakoli-kia R
Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Controlled, Noninferiority, Multicenter Trial of Systemic vs Intralesional Treatment With Meglumine Antimoniate for Cutaneous Leishmaniasis in Brazil.
Lyra MR; Oliveira LFA; Schubach AO; Sampaio RNR; Rodrigues BC; Hueb M; Cota G; Silva RE; Francesconi F; Pompilio MA; França AO; Amato VS; Souza RM; Oliveira RVC; Valete CM; Pimentel MIF
Clin Infect Dis; 2023 Aug; 77(4):574-582. PubMed ID: 37100061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]